Dynamic Center
In a study entitled "Tumor suppressor Par-4 activates autophagy-dependent ferroptosis" published in the international journal Communications Biology on June 17, 2024, Research by scientists at NYU ABU Dhabi and...
[View details]
Servier's oral IDH1/IDH2 dual inhibitor vorasidenib (Voranigo) was approved by the U.S. Food and Drug Administration (FDA) on August 6, according to FirstWordPHARMA. It is used in children and adults 12 years o...
[View details]
Rationale: Inducing cancer differentiation is a promising approach to treat cancer. Here, we identified chlorogenic acid (CA), a potential differentiation inducer, for cancer therapy, and elucidated the molecul...
[View details]
Glioblastoma is an aggressive tumor that is associated with distinctive infiltrating microglia/macrophages populations. Previous studies demonstrated that chlorogenic acid (5-caffeoylquinic acid, CHA), a phenol...
[View details]
